Evaluating initial screening practices for calcium dysregulation after acute traumatic spinal cord injury: a retrospective review

Evaluating initial screening practices for calcium dysregulation after acute traumatic spinal cord injury: a retrospective review

Introduction

Patients with traumatic spinal cord injuries and disorders (SCI/D) are known to suffer multisystem sequelae after initial traumatic neurologic event. Of particular interest is bone health and calcium homeostasis after SCI/D, particularly Vitamin D deficiency. It is known that those with SCI/D are at a higher risk of bone loss and fracture thought to be related to neuromuscular involvement, reduced mobility, and injury during transfer [1, 2]. It has been theorized that bone loss in acute traumatic SCI/D, coupled with hypercalcemia from immobilization, is related to a loss of balanced bone remodeling and increased level of bone resorption, with peak bone resorption occurring between 1 to 4 months post-acute injury and a decreasing but persisting post injury for several years [2]. Given the significant risk of morbidity and loss of function with fragility fractures in this population, there is a desire to promote preventative and therapeutic options to optimize bone health [3].

While there is a robust body of literature regarding vitamin D and bone health management after chronic TSCI, evidence and best practices in the acute setting are in comparison sparse [4]. Available studies that examine markers of calcium homeostasis dysfunction after acute traumatic SCI/D, such as when patients are admitted to inpatient rehabilitation facilities (IRFs), have noted vitamin D deficiency develops early after injury following the pattern of post injury bone resorption [2, 5,6,7]. However, initial hypercalcemia in the post traumatic period precludes the immediate use of Vitamin D supplementation until resolution months later, and in general there is no standard guideline for SCI induced calcium dysregulation management in the acute setting [2, 4].

In addition to IRFs, another site available to review for initial calcium homeostasis dysfunction would be acute care hospitals, which may have data evaluating initial laboratory markers and imaging, and may potentially serve as initial target times for treatment in the future when codified guidelines are created. In particular, data from acute hospitals assessing initial changes in serum and urinary calcium post-acute injury, along with associated lab and imaging values reflective of calcium dysregulation (parathyroid hormone [PTH], Vitamin D in various forms, phosphorus, N-terminal telopeptide, alkaline phosphatase, dual energy x-ray absorptiometry [DXA]) may help inform acute pathophysiology as well as ultimately developing standardized guidelines for treating acute calcium homeostasis dysfunction in traumatic SCI/D patients, particularly since there is no current consensus on treatment [2].

Calcium homeostasis dysregulation is associated with sequelae after acute traumatic SCI/D, and based on available literature this pathophysiology is poorly examined in the acute care setting [4]. This present study hopes to address this gap by examining whether calcium homeostasis markers were checked for patients admitted to an acute level 1 trauma center after initial traumatic SCI during initial hospitalization. It was hypothesized that besides calcium, most commonly used calcium homeostasis markers would not have been regularly checked. The findings of this present study would add to the sparse literature on how calcium dysregulation is evaluated after acute traumatic SCI/D and ideally inform future discussions on creating evaluation protocols.

Methods

Subjects

Institutional Review Board (IRB) exempted approval was obtained to retrospectively review patient charts to determine the frequency and values of calcium homeostasis markers in patients who sustained an acute traumatic SCI/D who were initially hospitalized to the institutional level 1 trauma center.

Inclusion criteria

Patients ages 18–89 with an acute traumatic SCI/D treated at the local institution with available and accessible chart data.

Exclusion criteria

Patients were excluded if they sustained an acute non-traumatic spinal cord injury (NTSCI), had a prior history of any type of SCI/D, or had a premorbid history of a condition causing calcium derangements (i.e., premorbid causing osteopenia, osteomalacia, osteoporosis, hypo or hypercalcemia, hypo or hyperphosphatemia, hypo or hyperparathyroidism, a malignancy with bony involvement, or a condition causing osteonecrosis, sclerosis, or hyperostosis of bone) mentioned on initial admission documentation on manual review.

A combination of ICD codes was provided (Table 1, bolded) to the hospital research informatics team to use as part of the inclusion criteria to define those with SCI/D. This was based on literature review of optimal positive predictive values and specificity of ICD 10 codes for traumatic SCI/D, predominately based on the work of Hagen’s team [8].

Table 1 ICD codes related to TSCI.
Full size table

With assistance from our informatics team, patient charts with above criteria were reviewed to see if any of the labs/imaging reports noted in Table 2 were present during the encounter. The data was subsequently reviewed manually by the research team and further filtered to ensure compliance with inclusion/exclusion criteria; of 6331 patients initially queried, 80 ultimately were deemed appropriate for inclusion in the study (Fig. 1).

Table 2 Diagnostic tests of interest.
Full size table
Fig. 1: Selection of subjects.
Evaluating initial screening practices for calcium dysregulation after acute traumatic spinal cord injury: a retrospective review

Initial query yield 6331 potential subjects; after exclusion criteria applied, 80 eligible subjected remained and were included in the study.

Full size image

Measures

Outcome measures

The primary outcome measure was the frequency for which specified lab and imaging values of interest were obtained during acute hospitalization for eligible patients.

Statistical analysis

Data analysis for descriptive statistics was conducted in IBM SPSS version 29. Summary statistics measured included frequency, mean, and standard deviation.

Results

Summary demographic information for the 80 subjects is listed in Table 3. Note etiology “Other” included other violent means of traumatic SCI besides gunshot wounds, sports injuries, and non-fall workplace related injuries. “Fall” includes both ground level and from height falls. ICD 10 codes reflect the combination previously described by Hagen et al.; note, patients may have had multiple ideal ICD 10 codes overlapping, or even other ICD 10 codes used to describe SCI/D which were not removed [8]. The total frequency of each of the described ICD 10 codes of interest is presented in Table 4 and Fig. 2.

Table 3 Demographics.
Full size table
Table 4 Frequency of ICD 10 codes of interest.
Full size table
Fig. 2: ICD codes of interest present in cohort.
figure 2

The ICD codes starting with S24.1 (representing unspecified injury to the thoracic spinal cord) were the most common diagnostic codes present in this cohort, with the remainder present as smaller percentages of the overall sample.

Full size image

The average age was 51.3 (SD: 19.2). As described previously in literature [9], there was a general trend for falls as the etiology of injury in older subjects, gunshot wounds (GSW) in the younger population, with a larger spread for motor vehicle accidents (MVA) and variability in the “other” class (Fig. 3).

Fig. 3: Etiology of injury based on age.
figure 3

Fall, gunshot wounds (GSW), motor vehicle accident (MVA), and Other (aggregated remaining etiologies) and their frequencies in the cohort are displayed.

Full size image

Of the labs and imaging reports of interest (Table 2), most were not present in this acute population. Of the labs present, values for the lab (or its key component of a panel) average and error/deviation are listed in Table 5. Calcium levels were present in all subjects, likely due to being present in the basic chemistry panel for the institution. Phosphorus was present for nearly every subject. Albumin and alkaline phosphatase were present in less than half of patients, and PTH was only obtained in one subject. Vitamin D was obtained in 12.5% of patients (mean value 28, standard deviation [SD] 23; mean days to check 1.5, SD 1.6).

Table 5 Components of available labs of interest.
Full size table

Discussion

Significance of data

As hypothesized, a majority of the labs or imaging reports of interest were not checked in this cohort. This highlights a major roadblock in identifying methods to mitigate the sequelae of calcium dysregulation: failing to identify early trends and points of potential intervention. For example, only 10 of 80, or 12.5% of patients in this cohort had a vitamin D level, in any form, checked during their acute admission. The mean vitamin D level of 28 is comparable to Waliullah et al.’s study of 85 patients with acute TSCI in a trauma center with a mean of 20.5 obtained during the first week from injury, and is typically considered “low” (i.e., below the recommended 40 ng/ml by the Endocrine Society) [4, 10].The results of this study support the need for developing acute care calcium homeostasis lab and imaging protocols to inform development of potential future treatment options – as well as to monitor for sequelae.

Specifically, obtaining and evaluating this information is critical in continuing to explore unique factors that may predispose certain individuals with TSCI to more sequelae than others. For example, Flueck et al. and Oleson et al. noted that certain groups (such as African Americans) have historically been noted to have lower Vitamin D levels, even in able bodied populations, and continue to demonstrate this trend post injury; seasonality (i.e. winter compared to summer) has been noted to adversely affect Vitamin D level as well including in those with SCI/D [1, 4, 11]. Other observed factors that may be associated include age, creatinine, body mass, and sodium levels [7, 12, 13]. Additionally, the role of vitamin D outside of simply bone health is being explored, such as an inflammatory marker and a neuroprotective agent, emphasizing the importance of its evaluation more broadly [13, 14].

At our institution, there is not a standard SCI calcium homeostasis lab order set or protocol. One could be reasonably incorporated at our local institution or at institutions across the nation; while the average acute care length of stay has decreased over time, the most recent estimates of an average of 19 days allows ample time to obtain and interpret calcium homeostasis labs [4, 9]. Future studies incorporating such a protocol could then shift to examining possible medical interventions to ultimately mitigate sequelae of calcium dysregulation.

Limitations

There were several limitations with this current study. One, a large portion of the potential cohort was removed due to absent patient data from initial queries by the informatics team. However, these were almost completely for injuries more than 3 years prior to the initial start of the study, without any apparent predilection for a patient characteristic. Notably, a recent migration between different electronic health record systems may have led to the loss of data that could be readily queried older than 3 years. Certainly, a larger potential sample size would have been preferred.

Another limitation was related to the classification of SCI/D. The aim was to utilize a method with high specificity to obtain an initial cohort with a high number of actual subjects with SCI/D. This was based on an ICD 10 combination previously found to have optimal specificity and positive predictive value by Hagen et al., though certainly the utilized combination may have excluded some with SCI/D [5]. It is unclear if this could have led to a significant bias in lab results. Notably, thoracic level injuries (predominately ICD code S14.1) were the most common SCI/D presentation in this cohort. This contrasts, however, with established literature [9] noting cervical level injuries (particularly incomplete tetraplegia) as the most common SCI/D, leading to the question of whether this was due to this unique cohort, a rather limited sample size, or a bias introduced from the combination of ICD 10 codes used. One option would have been to look those admitted to an IRF with a Centers for Medicare and Medicaid (CMS) Rehabilitation Diagnosis of spinal cord injury, and then review those initially seen at the acute care hospital and use the associated ICD codes for these patients. However, the concern was that patients who may have died, not transferred to our IRF, or went home may have been missed. Therefore, the literature was reviewed to observe ICD codes that have historically been used to describe SCI to remain more inclusive, and to reduce the risk of selection bias with this alternative. Future medical ontology research for better defining cohorts based on ICD or other related systems would prove useful in mitigating both this issue and more globally for other cohorts.

From a lab perspective, prior endocrine derangements that may have affected calcium homeostasis were reviewed, and subjects with these conditions were excluded; however, often with TSCI, patients may not be able to provide this history initially. Since only initial admission documentation was used to screen for this, it is possible some cases of this were missed.

Finally, this study cannot be generalized to those younger than 18 years of age or older than 89, nor to those with NTSCI with differences in acuity, etiology, pathophysiology, demographics, and outcomes compared to those with TSCI. As this was a single site study, the findings may reflect practices at this single level 1 trauma center and not necessary that of other institutions.

Conclusions

The aim for this initial study was to evaluate which, if any, calcium homeostasis markers are obtained in the acute setting for patients with TSCI; it was found that as hypothesized, most markers were either infrequently or never checked. We hope to use these results to facilitate the synthesis of a future prospective study where relevant markers are obtained for patients with TSCI acutely as well as serially in the chronic setting. A prospective study of this nature may aid in the further understanding of disorders that develop in these patients and allow for the creation of a calcium homeostasis protocol for this population. If such a protocol is created, we would then aim to examine the feasibility of an interventional study where medical management of calcium dysregulation is initiated in this population and outcomes tracked with markers from the created protocol. In doing so, we aim to minimize acute and chronic sequelae of calcium dysregulation after TSCI to bolster quality of life that may be adversely affected by sequelae of calcium dysregulation.

Related Articles

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia

X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert. Historically, these patients were treated with frequent doses of oral phosphate supplements and active vitamin D, which was of limited efficiency and associated with adverse effects. However, the management of XLH has evolved in the past few years owing to the availability of burosumab, a fully humanized monoclonal antibody that neutralizes circulating FGF23. Here, we provide updated clinical practice recommendations for the diagnosis and management of XLH to improve outcomes and quality of life in these patients.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Responses

Your email address will not be published. Required fields are marked *